Clinical Trials

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT07225127 2026-04-21

CISTO2

408 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT05796375 2026-04-20

ReplaceCysto

240 enrolled

Non-Muscle Invasive Bladder Neoplasms, Neoplasms

NCT07322263 2026-04-17

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

174 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

NCT03317158 2026-04-15

ADAPT-BLADDER

55 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05483868 2026-04-15

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

Phase 1 Recruiting

55 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT03528694 2026-04-14

POTOMAC

1,018 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06443944 2026-04-14

An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG

Available

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

NCT07529639 2026-04-14

Tumor Budding and T1 Substaging in Urothelial Bladder Cancer

Not yet recruiting

100 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Disease Progression

NCT05316155 2026-04-13

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

235 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06211764 2026-04-13

SunRISe-5

272 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06319820 2026-04-13

MoonRISe-1

Phase 3 Recruiting

641 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06877676 2026-04-13

Pre-Approval Expanded Access Study for TAR-200 Treating Physician Use

Approved for marketing

Non-Muscle Invasive Bladder Neoplasms

NCT07309445 2026-04-13

Nova-sTAR

150 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06995677 2026-04-09

SURF302

90 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT07511517 2026-04-09

BladMetrix

Active not recruiting

500 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Hypersensitivity

NCT06503614 2026-04-08

ENHANCE

60 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT07000084 2026-04-07

GAIN-BCG

Phase 3 Recruiting

330 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06833073 2026-04-06

INTerpath-011

308 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT05538663 2026-04-03

BRIDGE

870 enrolled

Phase 1 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT06253845 2026-04-01

Study of CG0070 After Transurethral Resection in Patients With IR NMIBC

20 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT07144319 2026-04-01

ENAiBLE

500 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT07505615 2026-04-01

VG-INFUSE Tria

Phase 1/2 Completed

20 enrolled

Phase 1/2 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT02138734 2026-03-31

A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

369 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms

NCT06704191 2026-03-30

In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial

40 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06800963 2026-03-27

ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG

40 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06810141 2026-03-27

ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer

Available

Non-Muscle Invasive Bladder Neoplasms

NCT07494864 2026-03-27

MiLUT

800 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT07495072 2026-03-27

PRO-GAG

Phase NA Recruiting

56 enrolled

Phase 3 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Cystitis, Interstitial

NCT07480356 2026-03-18

ADVANCED-3

284 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Neoplasms

NCT07313891 2026-03-17

BOOST

Phase 3 Withdrawn

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Neoplasms, Urologic Neoplasms

NCT04452591 2026-03-16

BOND-003

190 enrolled

Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ

NCT07474519 2026-03-16

Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer

Phase 4 Recruiting

40 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06173349 2026-03-13

PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer

Phase 1 Recruiting

12 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06919965 2026-03-13

MoonRISe-3

Phase 3 Recruiting

220 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT05943106 2026-03-11

PATAPSCO

100 enrolled

Phase 3 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT07464145 2026-03-11

RESCUE

393 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Neoplasms, Urologic Neoplasms

NCT07130578 2026-03-03

The Guiding Value of Liquid Biopsy Based on Urinary Tumor DNA/RNA in the Second Transurethral Resection of High-risk Non-muscle Invasive Bladder Cancer

60 enrolled

Phase 1/2 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT07445308 2026-03-03

The Study is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With NMIBC, and to Determine the RP2D of SPGL008 Alone or in Combination With BCG.To Evaluate the Preliminary Efficacy of SPGL008 Alone or in Combination With BCG.

120 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT04172675 2026-02-24

A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

Phase 2 Completed

107 enrolled 17 charts

Phase 3 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT07424287 2026-02-20

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

236 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT05710848 2026-02-19

A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer

75 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06637423 2026-02-19

TroFuse-027

32 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06026332 2026-02-17

ABLE-41

Terminated

202 enrolled

Phase 2 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06972615 2026-02-17

Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG Therapy

37 enrolled

Phase NA Active not recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT07391137 2026-02-09

CRUCIAL-R

250 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Recurrence

NCT06245603 2026-02-06

Hydeal Cyst

Phase NA Recruiting

200 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT05951179 2026-01-27

ADVANCED-2

131 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT06733363 2026-01-27

A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer

344 enrolled